ETHZilla Corporation Warrant (ATNFW)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ETHZilla Corporation Warrant (ATNFW) trades at $0.43 with AI Score 46/100 (Grade C). ETHZilla Corporation Warrant (ATNFW) is associated with 180 Life Sciences Corp. , a clinical-stage biotechnology company. Market cap: $2.60M, Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for ATNFW: ATNFW does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ATNFW against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ATNFW: the 1 perspectives are evenly split.
How is this calculated? →ETHZilla Corporation Warrant (ATNFW) Healthcare & Pipeline Overview
ETHZilla Corporation Warrant is linked to 180 Life Sciences Corp., a clinical-stage biotech firm targeting inflammatory diseases, fibrosis, and pain. Founded in 2016, the company leverages expertise from leading universities to develop novel therapeutics, operating within the competitive pharmaceutical sector.
What Is the Investment Thesis for ATNFW?
An investment in ETHZilla Corporation Warrant reflects the potential of 180 Life Sciences Corp.'s clinical-stage pipeline targeting inflammatory diseases, fibrosis, and pain. The company's approach of leveraging expertise from top universities provides a scientific foundation for its drug development programs. Key value drivers include successful clinical trial outcomes, regulatory approvals, and strategic partnerships. The company's small market capitalization and limited employee count (4) indicate a high-risk, high-reward profile. Investors should closely monitor clinical trial progress and regulatory milestones to assess the potential for long-term value creation. The beta of 0.41 suggests lower volatility compared to the overall market.
Based on FMP financials and quantitative analysis
ATNFW Key Highlights
- 180 Life Sciences Corp. focuses on developing drugs for inflammatory diseases, fibrosis, and pain.
- The company was founded in 2016 by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard.
- Headquartered in Palo Alto, CA, 180 Life Sciences leverages expertise from Oxford University, the Hebrew University, and Stanford University.
- The company operates as a clinical-stage biotechnology company.
- The company's market cap is $0.00B, indicating a micro-cap status.
Who Are ATNFW's Competitors?
ATNFW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| EIGRQ Eiger BioPharmaceuticals, Inc. | $8.50 | +6.25% | $12.59M | 54 |
| HIND Vyome Holdings Inc. | $2.23 | -3.26% | $12.53M | — |
| ATAI Atai Beckley NV is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders. The company | $4.88 | -5.97% | $1.80B | 68 |
| MEDS TRxADE HEALTH, Inc. | $7.59 | +4.55% | $13.28M | 63 |
| ONC BeOne Medicines Ltd. | $309.46 | +3.97% | $33.07B | 61 |
| NEUP Neuphoria Therapeutics Inc. | $3.44 | +1.78% | $18.59M | 60 |
| CGEM Cullinan Therapeutics, Inc. | $17.81 | +1.02% | $1.09B | 46 |
| AIXC AIxCrypto Holdings, Inc. | $1.12 | +1.82% | $5.78M | 46 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ATNFW's Key Strengths?
- Expertise in inflammatory diseases, fibrosis, and pain.
- Collaborations with leading universities.
- Proprietary drug candidates.
- Focus on unmet medical needs.
What Are ATNFW's Weaknesses?
- Clinical-stage company with no approved products.
- Limited financial resources.
- Small employee count.
- Dependence on clinical trial outcomes.
What Could Drive ATNFW Stock Higher?
- Clinical trial results for lead drug candidates.
- Regulatory submissions for potential drug approvals.
- Progress in research and development programs.
- Strategic partnerships and collaborations.
What Are the Key Risks for ATNFW?
- Clinical trial failures.
- Regulatory delays or rejections.
- Competition from other pharmaceutical companies.
- Dependence on securing additional funding.
- Patent litigation or challenges to intellectual property.
What Are the Growth Opportunities for ATNFW?
- Expansion into New Therapeutic Areas: 180 Life Sciences can expand its focus to include additional inflammatory and fibrotic diseases beyond its current pipeline. The market for autoimmune and inflammatory disease treatments is projected to reach $150 billion by 2028, presenting a significant growth opportunity. Successful development and commercialization of new therapies in these areas could drive substantial revenue growth for the company.
- Strategic Partnerships and Collaborations: Partnering with larger pharmaceutical companies or research institutions can provide 180 Life Sciences with access to additional resources, expertise, and funding. Collaborative agreements can accelerate drug development timelines, expand market reach, and reduce financial risk. The company can pursue partnerships for specific drug candidates or platform technologies.
- Advancements in Drug Delivery Technologies: Utilizing innovative drug delivery systems, such as targeted nanoparticles or sustained-release formulations, can improve the efficacy and safety of 180 Life Sciences' drug candidates. These technologies can enhance drug bioavailability, reduce side effects, and improve patient compliance. Investing in drug delivery research and development can provide a competitive advantage.
- Geographic Expansion: Expanding into new geographic markets, particularly in Asia and Europe, can increase the potential patient population for 180 Life Sciences' therapies. These regions have growing healthcare markets and increasing demand for innovative treatments. Establishing a presence in these markets through partnerships or direct operations can drive revenue growth and diversify the company's revenue streams.
- Orphan Drug Designations: Pursuing orphan drug designations for its therapies can provide 180 Life Sciences with market exclusivity, tax incentives, and expedited regulatory review. Orphan drug designations are granted to therapies targeting rare diseases or conditions affecting fewer than 200,000 people in the United States. This strategy can enhance the commercial attractiveness of the company's drug candidates.
What Opportunities Does ATNFW Have?
- Expansion into new therapeutic areas.
- Strategic partnerships and collaborations.
- Advancements in drug delivery technologies.
- Geographic expansion.
What Threats Does ATNFW Face?
- Clinical trial failures.
- Regulatory hurdles.
- Competition from established pharmaceutical companies.
- Patent expirations.
What Are ATNFW's Competitive Advantages?
- Proprietary drug candidates with patent protection.
- Expertise in inflammatory diseases, fibrosis, and pain.
- Collaborations with leading universities.
- Established clinical trial infrastructure.
What Does ATNFW Do?
180 Life Sciences Corp., associated with ETHZilla Corporation Warrant (ATNFW), is a clinical-stage biotechnology company established on September 7, 2016, by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard. Headquartered in Palo Alto, CA, the company focuses on developing innovative drugs to address unmet medical needs in inflammatory diseases, fibrosis, and pain management. The company leverages the combined expertise of researchers from Oxford University, the Hebrew University, and Stanford University to advance its therapeutic programs. 180 Life Sciences is dedicated to translating cutting-edge research into effective treatments for conditions with limited therapeutic options. Their approach involves identifying and validating novel targets, developing proprietary drug candidates, and conducting rigorous clinical trials to demonstrate safety and efficacy. The company's pipeline includes programs targeting various inflammatory and fibrotic diseases, as well as chronic pain conditions. By focusing on areas with significant unmet needs, 180 Life Sciences aims to improve the lives of patients suffering from these debilitating conditions.
What Products and Services Does ATNFW Offer?
- Develops novel drugs for inflammatory diseases.
- Creates therapies for fibrosis.
- Researches treatments for chronic pain.
- Leverages expertise from Oxford University, the Hebrew University, and Stanford University.
- Conducts clinical trials to evaluate drug safety and efficacy.
- Identifies and validates novel drug targets.
How Does ATNFW Make Money?
- Develops and patents novel drug candidates.
- Conducts preclinical and clinical research to demonstrate safety and efficacy.
- Seeks regulatory approval from agencies like the FDA.
- Out-licenses or commercializes approved drugs.
What Industry Does ATNFW Operate In?
180 Life Sciences Corp. operates within the competitive medical-pharmaceuticals industry. This sector is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition from established pharmaceutical companies and other biotechnology firms. Market trends include a growing demand for novel therapies targeting chronic diseases, advancements in drug delivery technologies, and increasing regulatory scrutiny. The company's success depends on its ability to successfully navigate these challenges and bring its drug candidates to market.
Who Are ATNFW's Key Customers?
- Patients suffering from inflammatory diseases.
- Patients with fibrotic conditions.
- Individuals experiencing chronic pain.
- Healthcare providers prescribing treatments.
Company Profile
ETHZilla Corporation Warrant operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Palo Alto, US. The company is led by CEO Lloyd Blair Jordan. ATNFW has traded publicly since 2017.
ETHZilla Corporation Warrant Financial Trajectory
ETHZilla Corporation Warrant (ATNFW) reported $2.9M in revenue for Q1 2026, reflecting 17.3% growth compared to the prior quarter. The company recorded a net loss of $76.3M, with diluted EPS of $-3.58. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare.
How ETHZilla Corporation Warrant Is Valued
ETHZilla Corporation Warrant carries a market capitalization of $2.60M, placing it in the micro-cap category. Relative to its peer group, ATNFW's quantitative score of 46/100 is below the peer average of 61/100.
Key Financial Metrics
Its free cash flow yield is -85.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.19 indicates the company holds enough short-term assets to cover its near-term obligations.
F-Score 4/9Financial Health
ETHZilla Corporation Warrant's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.
FY2026 estForward Outlook
Wall Street analysts project ETHZilla Corporation Warrant revenue of about $30.4M for fiscal 2026, with EPS near $57.00.
Net buyingInsider Activity
Over the past six months, ETHZilla Corporation Warrant insiders filed 8 SEC Form 4 transactions — 0 sales and 8 purchases. On net that is roughly 3.6M shares acquired (about $0) — insiders putting money in tends to read as conviction.
ATNFW Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that key stakeholders believe in upcoming growth.
- Social sentiment has shifted positively, with discussions around innovative projects and potential partnerships gaining traction.
- Community members are highlighting the unique market position of ETHZilla, suggesting it could capitalize on emerging trends in the crypto space.
- Increased engagement on social platforms indicates a growing interest in the company's developments, which could translate to broader market support.
Bear Case
- Concerns about regulatory challenges in the cryptocurrency sector have led to skepticism among some investors, impacting overall sentiment.
- Recent negative news cycles regarding crypto volatility have cast a shadow over the company's reputation, making some traders cautious.
- Some community members are voicing doubts about the sustainability of ETHZilla's business model amid fierce competition.
- Insider selling in prior periods may raise questions about long-term commitment from executives, fueling bearish sentiment among investors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $3M | -$76M | -$3.58 |
| Q4 2025 | $2M | -$230M | -$12.04 |
| Q3 2025 | $4M | -$209M | -$16.80 |
Based on FMP financials and quantitative analysis
ATNFW Latest News
No recent news available for ATNFW.
ATNFW Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ATNFW.
Price Targets
Wall Street price target analysis for ATNFW.
ATNFW MoonshotScore
What does this score mean?
The MoonshotScore rates ATNFW's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Lloyd Blair Jordan
Unknown
Information on Lloyd Blair Jordan's background is not available in the provided data. Without additional context, it's challenging to provide a comprehensive biography. Further research would be needed to determine his career history, educational background, and previous roles before managing 180 Life Sciences Corp.
Track Record: Information on Lloyd Blair Jordan's track record is not available in the provided data. It is unknown what key achievements, strategic decisions, or company milestones have occurred under his leadership. Further research would be needed to assess his performance and contributions to the company.
Common Questions About ATNFW (Healthcare)
What does ETHZilla Corporation Warrant do?
ETHZilla Corporation Warrant is associated with 180 Life Sciences Corp., a clinical-stage biotechnology company focused on developing novel drugs for inflammatory diseases, fibrosis, and pain. The company leverages expertise from leading universities to identify and validate drug targets, conduct clinical trials, and seek regulatory approvals. Their business model involves developing and patenting drug candidates, conducting research, and out-licensing or commercializing approved therapies. The company aims to address unmet medical needs in areas with limited treatment options.
What are the main risks for ATNFW?
The primary risks for ETHZilla Corporation Warrant, linked to 180 Life Sciences Corp., include clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies. Clinical trial failures can significantly impact the company's pipeline and valuation. Regulatory delays or rejections can delay or prevent drug approvals. Competition from larger companies with greater resources can limit market share. Additionally, the company faces risks related to securing additional funding and protecting its intellectual property.
What are the key factors to evaluate for ATNFW?
ETHZilla Corporation Warrant (ATNFW) holds an AI score of 46/100 (low). Not financial advice.
How frequently does ATNFW data refresh on this page?
ATNFW prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ATNFW's recent stock price performance?
ETHZilla Corporation Warrant (ATNFW) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Expertise in inflammatory diseases, fibrosis, and pain. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ATNFW overvalued or undervalued right now?
Valuing ETHZilla Corporation Warrant (ATNFW) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ATNFW?
Before investing in ETHZilla Corporation Warrant (ATNFW), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding ATNFW to a portfolio?
Key strength of ETHZilla Corporation Warrant (ATNFW): Expertise in inflammatory diseases, fibrosis, and pain. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data available.
- AI analysis pending.
- Information based on available sources as of 2026-03-18.